PF-Atlas › Clinical Trials › NCT05497284
To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
LTP001 · Phase 2
Registry ID
NCT05497284
Phase
Phase 2
Status
Terminated
Drug / intervention
LTP001
Sponsor
Novartis Pharmaceuticals
Start
2022-11-10
About this trial
LTP001 is evaluated in NCT05497284, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Novartis Pharmaceuticals. Current status: Terminated.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05497284 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.